Crossmark

Inhibition of DREAM-ATF6 interaction delays onset of cognition deficit in a mouse model of Huntington’s disease

Crossref DOI link: https://doi.org/10.1186/s13041-018-0359-6

Published Online: 2018-03-09

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

López-Hurtado, Alejandro

Burgos, Daniel F.

González, Paz

Dopazo, Xose M.

González, Valentina

Rábano, Alberto

Mellström, Britt

Naranjo, Jose R. https://orcid.org/0000-0002-0270-3469
Funding

Funding for this research was provided by:

Instituto de Salud Carlos III/CIBERNED

Madrid Regional Government (Neurodegmodels)

AEI-FEDER, EU (SAF2014-53412-R; SAF2017-89554-R)
License Information

Text and Data Mining valid from 2018-03-09
More Information

Article History

Received: 15 January 2018

Accepted: 5 March 2018

First Online: 9 March 2018

Ethics approval

: Behavioral tests and animal care were conducted in accordance with standard ethical guidelines (European Communities Directive 86/609 EEC; National Institutes of Health 1995). The CNB-CSIC and Community of Madrid ethical committees approved experiments with mice and use of human post-mortem samples (PROEX 28/05).

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.